Latest news with #VeradigmLLC
Yahoo
08-07-2025
- Health
- Yahoo
Enhanced Data Security and Compliance Strategies Driving Expansion, Collaborative Digital Health Initiatives Foster Growth
The global big data in healthcare market is set to grow from USD 31.46 Billion in 2024 to USD 121.85 Billion by 2034, at a CAGR of 14.50%. Growth is fueled by digital health tech adoption, AI integration, and increased funding. Key market players include Oracle, Optum Inc, and Veradigm LLC. Big Data in Healthcare Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Big Data in Healthcare Market Report and Forecast 2025-2034" report has been added to global big data in healthcare market was valued at USD 31.46 Billion in 2024 driven by the increasing geriatric population and integration of technological advancements in the healthcare sector across the globe. It is expected to grow at a CAGR of 14.50% during the forecast period of 2025-2034 and attain a market value of USD 121.85 Billion by 2034. Big data in healthcare refers to the vast volumes of structured and unstructured data generated from various sources, including electronic health records (EHRs), medical devices, clinical trials, genomic studies, and patient wearables. This data is analysed using advanced technologies like artificial intelligence, machine learning, and predictive analytics to identify patterns, enhance decision-making, and improve patient care. It enables personalised medicine, optimises healthcare delivery, and supports research for disease prevention and treatment. Challenges include ensuring data privacy, security, and interoperability. By harnessing big data effectively, healthcare systems can reduce costs, improve outcomes, and advance medical Data in Healthcare Market Growth Drivers Collaborative Digital Health Initiatives Foster Big Data Growth in HealthcareThe market is propelled by factors such as the growing adoption of digital health technologies and the increasing demand for data-driven healthcare solutions to improve patient care. For instance, In July 2024, WHO/Europe launched the Strategic Partners' Initiative for Data and Digital Health (SPI-DDH), which unites the 53 Member States of the WHO European Region and key stakeholders in digital health. This collaborative initiative seeks to address the challenges of digital health system transformation, ensuring that all patients and healthcare professionals benefit from safe, affordable, and patient-centric digital health technologies. The establishment of this network is poised to accelerate the integration of big data technologies across healthcare systems, fostering big data in healthcare market boost by enhancing data sharing, improving healthcare delivery, and driving innovations in predictive analytics, which will be key drivers of big data adoption in the healthcare sector in the coming Fundings to Significantly Support Big Data in Healthcare Market DemandThe market growth is expected to be influenced by the increased funding events among key players. For instance, in February 2023, ShiftMed, a mobile app that connects healthcare workers and providers, confirmed USD 200 million in fresh funding to fuel growth as investors continue to invest more in healthcare staffing companies. Such investments are expected to influence the market growth in the forecast period as these software apps use advanced technologies such as big data to process all the data of every worker they are employing and process it regularly. These approaches are anticipated to boost market growth in the forecast Acquisitions to Play a Pivotal Role in Big Data in Healthcare Market DevelopmentThe market is highly influenced by the increasing interest, investments, and adaptation of advanced technologies in the healthcare sector, bolstering the global big data in healthcare market growth. For instance, In November 2023, Thoma Bravo, a leading software investment firm acquired NextGen Healthcare, Inc. ("NextGen Healthcare" or the "Company"), a leading provider of innovative, cloud-based healthcare technology solutions, for USD 1.8 billion. With the completion of the transaction, NextGen Healthcare shareholders are entitled to receive USD 23.95 per share in cash. This investment by Thoma Bravo may enable NextGen Healthcare to share resources and develop better software solutions in healthcare such as enhancing data analytics capabilities within their platforms and leveraging big data to drive insights and improvements in patient care, operational efficiency, and Data in Healthcare Market TrendsAI and Machine Learning Integration Driving GrowthAI and machine learning technologies are becoming increasingly integrated with Big Data analytics in healthcare. These tools enable healthcare professionals to gain deeper insights from vast datasets, enhancing clinical decision-making and operational efficiency. AI algorithms can identify patterns in patient data, helping in predictive analytics for early disease detection and personalised treatments. Machine learning, when applied to Big Data, facilitates the automation of diagnostic processes, improves accuracy, and enables real-time monitoring of patients. As healthcare systems evolve towards value-based care, the reliance on AI-powered Big Data solutions is expected to expand, driving market Investment in Big Data-Driven Healthcare Staffing Solutions to Augment Big Data in Healthcare Market SizeIn February 2023, ShiftMed secured USD 200 million in funding to expand its mobile app, which connects healthcare workers and providers. Such investments highlight the growing reliance on big data technologies to streamline healthcare staffing. By leveraging big data, these platforms efficiently process vast amounts of worker data, including availability, credentials, and compliance, enabling real-time decision-making and optimisation of staffing resources. This trend underscores the value of big data in improving operational efficiency and workforce management in healthcare. With rising demand for efficient staffing solutions, such approaches are poised to drive significant market growth in the forecast in IT Infrastructure Boosting Big Data in Healthcare Market ValueHealthcare providers are investing heavily in IT infrastructure to support Big Data integration, leading to increased market value. Cloud computing, data warehouses, and advanced analytics platforms are central to managing and processing large volumes of healthcare data. This investment is critical for improving data accessibility, interoperability, and the speed of analysis. Governments and private entities are recognising the importance of modernising healthcare IT systems to enable data-driven healthcare. These investments not only help streamline operations but also improve patient care, accelerating the adoption of big data analytics. The healthcare IT infrastructure market is therefore poised for rapid Data Security and Compliance Strategies Driving Big Data in Healthcare Market ExpansionWith the increasing volume of sensitive healthcare data being processed, the need for robust security and regulatory compliance has become a key trend in the Big Data market. Healthcare data breaches and privacy concerns are prompting stronger safeguards and technologies to protect patient information. Organisations are focusing on adopting encryption methods, secure cloud solutions, and data access controls to ensure compliance with laws like HIPAA and GDPR. Furthermore, the rising implementation of blockchain technology in healthcare offers decentralised, secure data storage. As the demand for data protection rises, this trend will drive further market expansion and shape the future of healthcare data management. Key Questions Answered in the Big Data in Healthcare Market What was the global big data in healthcare market value in 2024? What is the global big data in healthcare market forecast outlook for 2025-2034? What is market segmentation based on product? How is the market segmented based on modes of deployment? What is market segmentation based on analytics type? How is the market segmented based on applications? How is the market segmented based on end users? What are the major factors aiding the global big data in healthcare market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major global big data in healthcare market trends? Which product will lead the market segment? Which modes of deployment will lead the market segment? Which analytics type will lead the market segment? Which application will lead the market segment? Which end user will lead the market segment? Who are the key players involved in the global big data in healthcare market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $31.46 Billion Forecasted Market Value (USD) by 2034 $121.85 Billion Compound Annual Growth Rate 14.5% Regions Covered Global Supplier Landscape Veradigm LLC Oracle Optum Inc. Hewlett Packard Enterprise (HPE) International Business Machines Corporation (IBM) Microsoft Corporation Epic Systems Corporation Abacus Insights Clarify Health Solutions Big Data in Healthcare Market SegmentationMarket Breakup by Product Software Electronic Health Record Software Practice Management Software Workforce Management Software Others Services Market Breakup by Mode of Deployment On - Premises Cloud Market Breakup by Analytics Type Descriptive Predictive Prescriptive Market Breakup by Applications Clinical Data Analytics Financial Analytics Operational Analytics Market Breakup by End User Hospitals and Clinics Finance and Insurance Agencies Research Organizations Others Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Big Data in Healthcare Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Wire
18-06-2025
- Business
- Business Wire
Veradigm to Release Business Update June 23 rd and Host Investor Call June 24 th
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Conference ID #13754301. A replay of the call will be available for a period of one year on the Veradigm investor relations website. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Business Wire
05-06-2025
- Business
- Business Wire
Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features expert guests including physicians, entrepreneurs, business leaders, and healthcare innovators – who will share their journeys, discuss challenges, and reveal the strategies that enable them to thrive. Through in-depth discussions, Smart Medicine will explore how providers are leveraging both time-tested and emerging strategies to enhance patient care, optimize business operations, and shape the future of healthcare. Future episode topics will include value-based care, medical entrepreneurship, point of care innovation, clinical and operational workflow practice management, revenue cycle management, patient and staff engagement and satisfaction, the impact of government and regulation on private practice, and the business of healthcare. 'By highlighting the real-world challenges, stakes, and rewards of these innovations, Smart Medicine will serve as a trusted guide for those navigating the intersection of medicine and business,' said Ray Joske, VP of Marketing at Veradigm. 'Each episode will follow an inspirational arc, spotlighting the obstacles overcome, the lessons learned, and the transformative impact of doing healthcare right.' Dr. Sigman is a nationally and internationally recognized leader in opioid-sparing surgery, with over 25 years of clinical experience as an orthopedic surgeon specializing in knee and shoulder procedures. Widely respected in professional education and medical device development, he has authored numerous peer-reviewed publications, and his TEDx talk on the evolution of the opioid crisis has been widely acclaimed within the industry. His podcast The Ortho Show became a go-to source for the latest in orthopedic news, growing to reach more than 8,000 listeners monthly, with more than 250 episodes. Click here to listen to new episodes of Smart Medicine. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Yahoo
02-04-2025
- Business
- Yahoo
Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency
Veradigm to provide a comprehensive solution set to optimize revenue cycle and coding processes CHICAGO, April 02, 2025--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Syracuse Orthopedic Specialists has selected elements from the Veradigm solution suite, Veradigm Revenue Cycle Services and Coding Services designed to support growth, improve cash flow and reduce costs. Syracuse Orthopedic Specialists, located near Syracuse, NY, provides total orthopedic care to the surrounding regions, and is currently utilizing Veradigm Revenue Analytics, Veradigm Practice Management and Veradigm Payerpath. Veradigm Revenue Cycle Services provides a robust suite of solutions designed to enhance healthcare revenue cycle management (RCM). This EHR-agnostic healthcare RCM service empowers healthcare providers to lower accounts receivable (AR) days, reduce claim errors, and generate fewer denials. Veradigm Coding Services seamlessly integrates with a practice's electronic health record (EHR) system, identifying deficiencies, optimizing coding and claims workflow. Veradigm works collaboratively with practices to manage complex exceptions, increase first-pass claims, and expedite revenue generation. "Veradigm has been a trusted partner throughout the years, so it really made sense for us to extend our agreement and adopt its turn-key revenue cycle management solution to complement our existing platform," said Mike Humphrey, Chief Executive Officer of Syracuse Orthopedic Specialists. "When we sought a partner to help streamline our business, we knew we could count on Veradigm's expertise to handle billing, reduce staff burden and increase revenue." "Today's healthcare provider practices are facing staff and practice operations challenges that can make navigating the end-to-end revenue cycle more difficult than ever," said Tom Langan, Interim Chief Executive Officer of Veradigm. "Our revenue cycle management solution will streamline workflow and free up time and resources for Syracuse Orthopedic Specialists. We are excited to extend our relationship with the Syracuse Orthopedic Specialist team." About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. View source version on Contacts Investors:Jenny Media:Amanda
Yahoo
18-03-2025
- Business
- Yahoo
Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements
CHICAGO, March 18, 2025--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that it filed its comprehensive Annual Report on Form 10-K for the year ended December 31, 2022, which also contains certain restated financial statements for periods in fiscal year 2022, 2021 and 2020 (the "2022 Form 10-K"), with the Securities and Exchange Commission ("SEC"). "This filing represents an important step toward regaining compliance with our financial reporting obligations," said Tom Langan, Interim Chief Executive Officer of Veradigm. "We remain focused on remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing against our growth strategy to deliver end-to-end solutions for our clients, and relisting our common stock. I would like to recognize our Veradigm employees for the dedication and work to earn our customers' business every day." "We are pleased to have filed the 2022 Form 10-K as part of a comprehensive undertaking that involved a detailed and thorough examination of our financial statements, as well as our accounting policies and processes," said Lee Westerfield, Interim Chief Financial Officer of Veradigm. The adjustments to the Company's revenue from continuing operations in the 2022 Form 10-K are consistent with the amounts that were estimated in the Form 12b-25 filed by the Company on March 4, 2025. For further information regarding the circumstances that led to the financial statement restatements and the Company's remediation efforts, please see the sections entitled "Explanatory Note" and Item 9A, "Controls and Procedures", in the 2022 Form 10-K. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. Table 1 Veradigm Inc. Condensed Consolidated Balance Sheets (In millions) (Unaudited) (As Restated) (As Restated) December 31, December 31, December 31, 2022 2021 2020 ASSETS Current assets: Cash and cash equivalents $446.6 $133.7 $472.8 Restricted cash 1.3 1.3 5.5 Accounts receivable, net 119.1 119.7 122.5 Contract assets 56.6 65.2 63.2 Income tax receivable 0.0 0.0 25.4 Prepaid expenses and other current assets 56.0 51.8 47.7 Current assets attributable to discontinued operations 0.0 277.6 349.2 Total current assets $679.6 $649.3 $1,086.3 Fixed assets, net 9.5 17.7 29.2 Software development costs, net 75.1 81.2 81.6 Intangible assets, net 89.3 149.7 166.0 Goodwill 532.6 498.4 498.6 Deferred taxes, net 37.2 0.0 0.0 Contract assets - long-term 0.0 0.0 0.0 Right-of-use assets - operating leases 12.0 18.3 27.1 Other assets 69.4 79.7 65.2 Long-term assets attributable to discontinued operations 0.0 816.8 909.5 Total assets $1,504.7 $2,311.1 $2,863.5 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $30.9 $2.2 $12.8 Accrued expenses 66.8 62.9 68.3 Accrued compensation and benefits 35.9 30.3 41.8 Deferred revenue 90.1 87.9 115.3 Current operating lease liabilities 6.6 6.1 6.6 Current liabilities attributable to discontinued operations 0.0 299.0 697.3 Total current liabilities 230.3 488.4 942.1 Long-term debt 200.4 350.1 167.6 Deferred revenue 0.0 0.2 0.1 Deferred taxes, net 0.0 18.7 18.2 Long-term operating lease liabilities 12.4 16.8 22.9 Other liabilities 44.1 33.8 32.5 Long-term liabilities attributable to discontinued operations 0.0 42.7 66.7 Total liabilities $487.2 $950.7 $1,250.1 Total stockholders' equity $1,017.5 $1,360.4 $1,613.4 Total liabilities and stockholders' equity $1,504.7 $2,311.1 $2,863.5 Table 2 Veradigm Inc. Condensed Consolidated Statements of Operations (In millions, except per share amounts) (Unaudited) Twelve Months Ended December 31, (As Restated) (As Restated) 2022 2021 2020 Revenue: Provider $465.9 $478.4 $463.0 Payer & Life Science 122.1 99.0 93.1 Total Revenue 588.0 577.4 556.1 Cost of revenue: Provider 232.8 244.2 247.8 Payer & Life Science 46.8 50.8 44.1 Total cost of revenue 279.6 295.0 291.9 Gross profit 308.4 282.4 264.2 Selling, general and administrative expenses 169.2 111.8 155.7 Research and development 97.9 84.1 78.6 Asset impairment charges 7.5 0.5 10.2 Amortization of intangible and acquisition-related assets 60.9 9.3 11.9 Income (loss) from operations (27.1 ) 76.7 7.8 Interest income (expense), net (a) (1.7 ) (12.7 ) (33.8 ) Other income (expense) (35.0 ) 93.7 13.3 Income (loss) before income taxes (63.8 ) 157.7 (12.7 ) Income tax (provision) benefit 43.8 (29.9 ) (15.0 ) Income (loss) from continuing operations, net of tax (20.0 ) 127.8 (27.7 ) Income (loss) from discontinued operations (7.1 ) 15.8 (70.9 ) Gain (loss) on sale of discontinued operations (10.3 ) 0.6 1,156.8 Income tax (provision) benefit from discontinued operations (49.0 ) (4.5 ) (362.2 ) Income (loss) from discontinued operations, net of tax (66.4 ) 11.9 723.7 Net Income (loss) ($86.4 ) $139.7 $696.0 Diluted earnings per Common Share: Income (loss) from continuing operations, net of tax ($20.0 ) $127.8 ($27.7 ) Plus: Interest expense, net of tax1 $0.0 $0.0 $0.0 Income (loss) from continuing operations2 (20.0 ) 127.8 (27.7 ) Income (loss) from discontinued operations, net of tax (66.4 ) 11.9 723.7 Net Income (loss)2 ($86.4 ) $139.7 $696.0 Income (loss) from continuing operations per share - basic ($0.18 ) $0.98 ($0.17 ) Income (loss) from discontinued operations per share - basic ($0.59 ) $0.09 $4.54 Income (loss) per share - basic ($0.77 ) $1.07 $4.37 Income (loss) from continuing operations per share - diluted2 ($0.18 ) $0.92 ($0.17 ) Income (loss) from discontinued operations per share - diluted ($0.59 ) $0.09 $4.54 Income (loss) per share - diluted2 ($0.77 ) $1.01 $4.37 Weighted average common shares outstanding: Basic 112.1 130.1 159.3 Diluted 112.1 138.7 159.3 Twelve Months Ended December 31, Restated Restated 2022 2021 2020 (a) Interest income (expense), net Interest expense (4.1 ) (5.4 ) (18.3 ) Interest income 4.7 0.2 0.5 Non-cash charges to interest expense (2.3 ) (7.5 ) (16.0 ) Interest income (expense), net ($1.7 ) ($12.7 ) ($33.8 ) 1Associated with 0.875% Convertible Senior Notes 2Net of tax after the effect of assumed conversions of convertible notes Table 3 Veradigm Inc. Condensed Non-GAAP Financial Information (In millions, except per share amounts and percentages) (Unaudited) Twelve Months Ended December 31, (AsRestated) (AsRestated) 2022 2021 2020 Revenue, GAAP $588.0 $577.4 $556.1 Gross profit, GAAP $308.4 $282.4 $264.2 Depreciation and amortization 37.0 37.5 33.6 Acquisition-related amortization 6.8 7.1 9.9 Stock-based compensation expense 1.3 1.1 1.7 Total non-GAAP gross profit $353.5 $328.1 $309.4 Non-GAAP Gross margin 1 60.1 % 56.8 % 55.6 % Net Income ($86.4 ) $139.7 $696.0 Less: Loss (income) from discontinued operations $7.1 ($15.8 ) $70.9 Loss (gain) on sale of business, net from discontinued operations $10.3 ($0.6 ) ($1,156.8 ) Income tax provision (benefit) from discontinued operations $49.0 $4.5 $362.2 Income (loss) from continuing operations, net of tax, GAAP ($20.0 ) $127.8 ($27.7 ) Plus: Interest (income) expense, net 1.7 12.7 33.8 Other (income) expense 35.0 (93.7 ) (13.3 ) Depreciation and amortization 113.5 65.3 71.2 Income tax (benefit) provision (43.8 ) 29.9 15.0 Stock-based compensation expense 29.6 13.6 13.5 Asset impairment charges 7.5 0.5 10.2 Transaction and other 17.9 12.6 19.6 Adjusted EBITDA $141.4 $168.7 $122.3 Adjusted EBITDA margin 2 24.0 % 29.2 % 22.0 % Net Income ($86.4 ) $139.7 $696.0 Plus: Interest expense, net of tax4 0.0 0.0 0.0 Net Income (loss)3 ($86.4 ) $139.7 $696.0 Loss (income) from discontinued operations 7.1 (15.8 ) 70.9 (Gain) on sale of business, net from discontinued operations 10.3 (0.6 ) (1,156.8 ) Income tax provision (benefit) from discontinued operations 49.0 4.5 362.2 Income (loss) from continuing operations3 ($20.0 ) $127.8 ($27.7 ) Less: Interest expense, net of tax4 0.0 0.0 0.0 Income (loss) from continuing operations, net of tax ($20.0 ) $127.8 ($27.7 ) Acquisition-related amortization 67.7 16.3 21.7 Stock-based compensation expense 29.6 13.6 13.5 Transaction and other 17.9 12.6 19.6 Other non-operating (income) expense 16.0 0.3 16.5 Asset impairment charges 7.5 0.0 10.2 Tax rate alignment (61.8 ) (18.2 ) (1.6 ) Non-GAAP net income $56.9 $152.4 $52.2 GAAP effective tax rate 69 % 19 % -120 % Non-GAAP effective tax rate 24 % 24 % 24 % Weighted shares outstanding - basic 112.1 130.1 159.3 Weighted shares outstanding - diluted 112.1 138.7 159.3 The net effect of convertible notes and note hedges 5.0 (2.8 ) 2.7 Non-GAAP Weighted shares outstanding - diluted 117.1 135.9 162.0 Income (loss) from continuing operations per share - diluted3 ($0.18 ) $0.92 ($0.17 ) Income (loss) from discontinued operations per share - diluted ($0.59 ) $0.09 $4.54 Income (loss) per share - diluted3 ($0.77 ) $1.01 $4.37 Non-GAAP Income (loss) per share - diluted $0.49 $1.12 $0.32 1 Non-GAAP Gross margin is calculated by dividing Non-GAAP Gross profit by revenue. 2 Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue. 3 Net of tax after the effect of assumed conversions of convertible notes 4 Associated with 0.875% Convertible Senior Notes Table 4 Veradigm Inc. Supplemental Condensed Non-GAAP Financial Information (In millions, except per share amounts) (unaudited) 2020 2021 2022 (As Restated) (As Restated) (As Restated) (As Restated) (As Restated) Total Q1 Q2 Q3 Q4 Total Q1 Q2 Q3 Q4 Total Provider Revenue $463.0 $113.2 $117.3 $118.7 $129.2 $478.4 $113.4 $114.1 $116.0 $122.4 $465.9 Gross profit, Non-GAAP $254.6 $63.3 $65.7 $64.4 $77.5 $270.9 $64.6 $63.0 $66.6 $73.2 $267.4 Gross margin, Non-GAAP 1 55.0 % 55.9 % 56.0 % 54.3 % 60.0 % 56.6 % 57.0 % 55.2 % 57.4 % 59.8 % 57.4 % Payer & Life Science Revenue $93.1 $21.6 $23.7 $25.7 $28.0 $99.0 $23.5 $34.4 $30.4 $33.8 $122.1 Gross profit, Non-GAAP $54.8 $11.9 $13.6 $14.8 $16.9 $57.2 $14.8 $24.7 $21.5 $25.1 $86.1 Gross margin, Non-GAAP 1 58.9 % 55.1 % 57.4 % 57.6 % 60.4 % 57.8 % 63.0 % 71.8 % 70.7 % 74.3 % 70.5 % Total Veradigm Revenue $556.1 $134.8 $141.0 $144.4 $157.2 $577.4 $136.9 $148.5 $146.4 $156.2 $588.0 Gross profit, Non-GAAP $309.4 $75.2 $79.3 $79.2 $94.4 $328.1 $79.4 $87.7 $88.1 $98.3 $353.5 Gross margin, Non-GAAP 1 55.6 % 55.8 % 56.2 % 54.8 % 60.1 % 56.8 % 58.0 % 59.1 % 60.2 % 62.9 % 60.1 % Adjusted EBITDA $122.3 $32.4 $38.9 $36.8 $60.6 $168.7 $27.7 $37.5 $33.9 $42.3 $141.4 Adjusted EBITDA margin2 22.0 % 24.0 % 27.6 % 25.5 % 38.5 % 29.2 % 20.2 % 25.3 % 23.2 % 27.1 % 24.0 % Net Income, Non-GAAP $52.2 $14.8 $28.8 $27.2 $81.6 $152.4 $10.5 $6.6 $15.7 $24.0 $56.9 Non-GAAP Weighted shares outstanding - diluted 162.0 146.5 142.0 128.6 125.3 135.9 125.1 119.6 113.3 111.1 117.1 Non-GAAP Income (loss) per share - diluted $0.32 $0.10 $0.20 $0.21 $0.65 $1.12 $0.08 $0.06 $0.14 $0.22 $0.49 1 Non-GAAP Gross margin is calculated by dividing Non-GAAP Gross profit by revenue. 2 Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue. Table 5 Veradigm Inc. Supplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details (In millions) (unaudited) 2020 2021 2022 (As Restated) (As Restated) (As Restated) (As Restated) (As Restated) Total Q1 Q2 Q3 Q4 Total Q1 Q2 Q3 Q4 Total Provider Revenue $463.0 $113.2 $117.3 $118.7 $129.2 $478.4 $113.4 $114.1 $116.0 $122.4 $465.9 Gross profit, GAAP $215.2 $54.2 $56.4 $55.2 $68.4 $234.2 $55.9 $54.7 $58.3 $64.2 $233.1 Depreciation and amortization 29.8 7.7 7.9 7.8 7.1 30.5 7.2 6.9 6.8 7.5 28.4 Acquisition-related amortization 8.1 1.3 1.3 1.3 1.4 5.3 1.1 1.1 1.1 1.4 4.7 Stock-based compensation expense 1.5 0.1 0.1 0.1 0.6 0.9 0.4 0.3 0.4 0.1 1.2 Gross profit, Non-GAAP $254.6 $63.3 $65.7 $64.4 $77.5 $270.9 $64.6 $63.0 $66.6 $73.2 $267.4 Payer & Life Science Revenue $93.1 $21.6 $23.7 $25.7 $28.0 $99.0 $23.5 $34.4 $30.4 $33.8 $122.1 Gross profit, GAAP $49.0 $9.6 $11.3 $12.4 $14.9 $48.2 $12.1 $21.9 $18.7 $22.6 $75.3 Depreciation and amortization 3.8 1.7 1.7 1.8 1.8 7.0 2.2 2.2 2.2 2.0 8.6 Acquisition-related amortization 1.8 0.5 0.5 0.5 0.3 1.8 0.5 0.6 0.6 0.4 2.1 Stock-based compensation expense 0.2 0.1 0.1 0.1 (0.1 ) 0.2 0.0 0.0 0.0 0.1 0.1 Gross profit, Non-GAAP $54.8 $11.9 $13.6 $14.8 $16.9 $57.2 $14.8 $24.7 $21.5 $25.1 $86.1 Table 6 Veradigm Inc. Supplemental Non-GAAP Financial Information Reconciliation - Financial Trend Details (In millions, except per share amounts) (unaudited) 2020 2021 2022 (As Restated) (As Restated) (As Restated) (As Restated) (As Restated) Total Q1 Q2 Q3 Q4 Total Q1 Q2 Q3 Q4 Total Total Veradigm Revenue $556.1 $134.8 $141.0 $144.4 $157.2 $577.4 $136.9 $148.5 $146.4 $156.2 $588.0 Gross profit, GAAP $264.2 $63.8 $67.7 $67.6 $83.3 $282.4 $68.0 $76.6 $77.0 $86.8 $308.4 Depreciation and amortization 33.6 9.4 9.6 9.6 8.9 37.5 9.4 9.1 9.0 9.5 37.0 Acquisition-related amortization 9.9 1.8 1.8 1.8 1.7 7.1 1.6 1.7 1.7 1.8 6.8 Stock-based compensation expense 1.7 0.2 0.2 0.2 0.5 1.1 0.4 0.3 0.4 0.2 1.3 Gross profit, Non-GAAP $309.4 $75.2 $79.3 $79.2 $94.4 $328.1 $79.4 $87.7 $88.1 $98.3 $353.5 Net Income (loss) $696.0 $20.3 $31.4 $14.3 $73.7 $139.7 $23.6 ($83.0 ) ($0.4 ) ($26.6 ) ($86.4 ) Interest expense, net of tax2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 Net Income (loss)1 $696.0 $20.3 $31.4 $14.3 $73.7 $139.7 $24.1 ($83.0 ) ($0.4 ) ($26.6 ) ($86.4 ) Loss (income) from discontinued operations 70.9 (19.0 ) (3.2 ) 6.8 (0.4 ) (15.8 ) 4.3 3.0 0.5 (0.7 ) 7.1 Loss (gain) on sale of business, net from discontinued operations (1,156.8 ) (0.6 ) 0.0 0.0 0.0 (0.6 ) 0.0 10.3 0.0 0.0 10.3 Income tax provision (benefit) from discontinued operations 362.2 5.1 0.2 (2.0 ) 1.2 4.5 (9.8 ) 61.4 (3.0 ) 0.4 49.0 Income (loss) from continuing operations1 ($27.7 ) $5.8 $28.4 $19.1 $74.5 $127.8 $18.6 ($8.3 ) ($2.9 ) ($26.9 ) ($20.0 ) Interest expense, net of tax2 0.0 0.0 0.0 0.0 0.0 0.0 (0.5 ) 0.0 0.0 0.0 0.0 Net Income (loss) from continuing operations, GAAP ($27.7 ) $5.8 $28.4 $19.1 $74.5 $127.8 $18.1 ($8.3 ) ($2.9 ) ($26.9 ) ($20.0 ) Interest (income) expense, net 33.8 2.8 2.9 3.6 3.4 12.7 2.1 1.8 (0.4 ) (1.8 ) 1.7 Other (income) expense (13.3 ) (1.2 ) (18.3 ) (14.0 ) (60.2 ) (93.7 ) (0.1 ) 30.0 3.9 1.2 35.0 Depreciation and amortization 71.2 16.7 16.7 16.5 15.4 65.3 15.7 28.4 34.6 34.8 113.5 Income tax (benefit) provision 15.0 2.9 3.6 5.9 17.5 29.9 (23.7 ) (28.0 ) (10.0 ) 17.9 (43.8 ) Stock-based compensation expense 13.5 3.6 3.5 3.2 3.3 13.6 6.9 10.5 5.7 6.5 29.6 Asset impairment charges 10.2 0.0 0.2 0.4 (0.1 ) 0.5 2.0 0.4 1.2 3.9 7.5 Transaction and other 19.6 1.8 1.9 2.1 6.8 12.6 6.7 2.7 1.8 6.7 17.9 Adjusted EBITDA $122.3 $32.4 $38.9 $36.8 $60.6 $168.7 $27.7 $37.5 $33.9 $42.3 $141.4 Income (loss) from continuing operations, net of tax, as reported ($27.7 ) $5.8 $28.4 $19.1 $74.5 $127.8 $18.1 ($8.3 ) ($2.9 ) ($26.9 ) ($20.0 ) Acquisition-related amortization 21.7 4.1 4.1 4.1 4.0 16.3 3.8 17.0 23.5 23.4 67.7 Stock-based compensation expense 13.5 3.6 3.5 3.2 3.3 13.6 6.9 10.5 5.7 6.5 29.6 Transaction and other 19.6 1.8 1.9 2.1 6.8 12.6 6.7 2.7 1.8 6.7 17.9 Other non-operating (income) expense 16.5 1.3 (3.6 ) 1.3 1.3 0.3 0.0 14.4 1.4 0.2 16.0 (Gain) loss on business transactions 0.0 0.0 0.0 (0.0 ) 0.0 (0.0 ) 0.0 0.0 0.0 (0.0 ) (0.0 ) Asset impairment charges 10.2 0.0 0.0 0.0 0.0 0.0 2.0 0.4 1.2 3.9 7.5 Tax rate alignment (1.6 ) (1.8 ) (5.5 ) (2.6 ) (8.3 ) (18.2 ) (27.0 ) (30.1 ) (15.0 ) 10.2 (61.8 ) Non-GAAP net income $52.2 $14.8 $28.8 $27.2 $81.6 $152.4 $10.5 $6.6 $15.7 $24.0 $56.9 GAAP effective tax rate -120 % 34 % 11 % 24 % 19 % 19 % 425 % 77 % 77 % -201 % 69 % Non-GAAP effective tax rate 24 % 24 % 24 % 24 % 24 % 24 % 24 % 24 % 24 % 24 % 24 % Weighted shares outstanding - basic 159.3 140.2 136.6 123.9 120.1 130.1 115.9 114.3 110.2 108.1 112.1 Weighted shares outstanding - diluted 162.0 149.1 145.3 131.4 127.8 138.7 138.7 118.7 113.3 111.1 116.8 Less the net effect of convertible notes and note hedges 0.0 (2.6 ) (3.3 ) (2.8 ) (2.5 ) (2.8 ) (13.6 ) 0.9 0.0 0.0 0.3 Non-GAAP Weighted shares outstanding - diluted 162.0 146.5 142.0 128.6 125.3 135.9 125.1 119.6 113.3 111.1 117.1 Income (loss) from continuing operations per share - diluted2 ($0.17 ) $0.04 $0.20 $0.15 $0.58 $0.92 $0.13 ($0.07 ) ($0.03 ) ($0.25 ) ($0.18 ) Income (loss) from discontinued operations per share - diluted $4.54 $0.10 $0.02 ($0.04 ) ($0.01 ) $0.09 $0.04 ($0.65 ) $0.02 $0.00 ($0.59 ) Income (loss) per share - diluted2 $4.37 $0.14 $0.22 $0.11 $0.57 $1.01 $0.17 ($0.72 ) ($0.01 ) ($0.25 ) ($0.77 ) Non-GAAP Net Income (loss) per share - diluted $0.32 $0.10 $0.20 $0.21 $0.65 $1.12 $0.08 $0.06 $0.14 $0.22 $0.49 1Net of tax after the effect of assumed conversions of convertible notes 2Associated with 0.875% Convertible Senior Notes Explanation of Non-GAAP Financial Measures Veradigm reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Veradigm presents non-GAAP gross profit, gross margin, Adjusted EBITDA, Adjusted EBITDA margin, effective income tax rate, net income (loss), diluted weighted shares outstanding and diluted income (loss) per share, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. The definitions of non-GAAP financial measures are presented below: Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related amortization; stock-based compensation expense; and depreciation and amortization. Reconciliations to GAAP gross profit are found in Tables 3, 5, and 6 within this press release. Non-GAAP gross margin is a non-GAAP measure that is calculated by dividing non-GAAP gross profit by revenue. Adjusted EBITDA is a non-GAAP financial measure and consists of GAAP net income/(loss) from continuing operations and adjusts for: interest (income)/expense, net; other (income)/expense; depreciation and amortization; income tax (benefit)/provision; stock-based compensation expense; asset impairment charges; and transaction and other revenue and expenses. Reconciliations to GAAP net income/(loss) are found in Tables 3 and 6 within this press release. Adjusted EBITDA margin is a non-GAAP measure that is calculated by dividing Adjusted EBITDA by revenue. See the reconciliations in Tables 3 and 6 within this press release with respect to Adjusted EBITDA. Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income tax rate, Veradigm effective state income tax rate and adjustments for permanent differences. Non-GAAP net income (loss) consists of GAAP net income/(loss), as reported, less discontinued operations and adds back acquisition-related amortization; stock-based compensation expense; asset impairment charges; transaction and other revenue and expenses; and non-cash charges to interest expense and other. Non-GAAP net income also includes a GAAP to non-GAAP tax rate alignment adjustment. Reconciliations to GAAP net income (loss) are found in Tables 3 and 6 within this press release. Non-GAAP diluted weighted shares outstanding consists of diluted weighted shares outstanding, as reported, less the dilutive impact of the Company's 0.875% convertible notes (the "convertible notes") due to the intent to settle the principal in cash and shares to be delivered at settlement by the convertible note hedge. Non-GAAP diluted income (loss) per share consists of non-GAAP net income, as defined above, divided by non-GAAP diluted weighted shares outstanding, as defined above, during the applicable period. Management believes that non-GAAP gross profit, gross margin, Adjusted EBITDA, Adjusted EBITDA margin, effective income tax rate, net income (loss), diluted weighted shares outstanding and diluted income (loss) per share provide useful supplemental information to management and investors regarding the underlying performance of Veradigm business operations. Acquisition accounting adjustments and transaction and other revenue and expenses recorded in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein. Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP diluted income (loss) per share and Adjusted EBITDA to measure achievement under Veradigm's stock and cash incentive compensation plans. Note, however, that non-GAAP diluted income (loss) per share and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Veradigm's results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within this press release. Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Veradigm excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP gross margin, non-GAAP net income, Adjusted EBITDA and Adjusted EBITDA margin because it believes (i) the amount of such expenses in any specific period may not directly correlate with the underlying performance of Veradigm's business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods. Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Veradigm excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP gross margin, non-GAAP net income (loss) and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Veradigm business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods. Asset impairment charges. Asset impairment charges, which are excluded from Adjusted EBITDA, Adjusted EBITDA margin and Non-GAAP net income (loss), reflect non-cash charges related to the abandonment of certain leased spaces and write-offs based on management's assessment of the likelihood of near-term recovery of certain investments' value. Depreciation and Amortization. Depreciation and amortization, which are excluded from non-GAAP gross profit, non-GAAP gross margin, Adjusted EBITDA and Adjusted EBITDA margin, are non-cash expenses arising from allocating the cost of fixed assets, intangibles and capitalized software over time. Transaction and Other. Transaction and other revenue and expenses relate to certain favorable and unfavorable legal settlements, severance, investigations, internal reviews, restatement-related accounting and legal advisory services and other charges incurred in connection with activities that are considered not reflective of our core business. Veradigm excludes transaction and other revenue and expenses from non-GAAP net income (loss), Adjusted EBITDA and Adjusted EBITDA margin because it believes (i) the amount of such revenue or expenses in any specific period may not directly correlate to the underlying performance of Veradigm business operations and (ii) such revenue or expenses can vary significantly between periods. Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense include the amortization of the discount and debt issuance costs associated with the convertible notes. Other includes certain other income and expense and impairments on long-term investments and gains and losses on business transactions and certain asset disposals. Tax Rate Alignment. Tax rate alignment aligns the applicable period's effective tax rate to the expected annual non-GAAP effective tax rate. View source version on Contacts Investors: Jenny Media: Amanda Sign in to access your portfolio
